A Randomized Phase 2 Trial of Cediranib and Olaparib Compared to Bevacizumab in Patients With Recurrent Glioblastoma Who Have Not Received Prior VEGF Therapy
Not yet recruiting
Phase of Trial: Phase II
Latest Information Update: 16 Aug 2017
At a glance
- Drugs Cediranib (Primary) ; Olaparib (Primary) ; Bevacizumab
- Indications Glioblastoma
- Focus Therapeutic Use
- 23 Apr 2017 Planned primary completion date changed from 1 Sep 2019 to 30 Sep 2019.
- 23 Apr 2017 Planned initiation date changed from 1 Sep 2017 to 15 Sep 2017.
- 30 Nov 2016 New trial record